Clinical Trials Logo

Clinical Trial Summary

To determine the pharmacokinetic profile and safety of udenafil in adolescents with Fontan physiology and to assess the short-term pharmacodynamic effect of udenafil on pharmacodynamic measures of exercise capacity, ventricular performance, and vascular function.


Clinical Trial Description

A dose escalation trial to determine the pharmacokinetics, safety and tolerance of udenafil in male and female adolescent subjects with single ventricle physiology that that have undergone the Fontan surgical procedure. Pharmacodynamic data will also be collected to evaluate the effect of udenafil on acute exercise performance, peripheral vascular function and indices of myocardial performance. Five udenafil cohorts will be evaluated in additional to one drug free cohort ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Single Ventricle Heart Disease After Fontan Surgery

NCT number NCT02201342
Study type Interventional
Source Mezzion Pharma Co. Ltd
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 2014
Completion date April 2015

See also
  Status Clinical Trial Phase
Completed NCT01815502 - Study of Effects of Sildenafil on Patients With Fontan Heart Circulation Phase 4